Perform liver function tests before initiating treatment & periodically thereafter. Patient who consume substantial quantities of alcohol &/or have history of liver disease. Consider potential risk of hemorrhagic stroke before initiating treatment in patients w/ recent stroke or transient ischemic attack. Discontinue use if markedly elevated creatinine phosphokinase levels occur or myopathy is diagnosed or suspected. Increased risk of myopathy w/ cyclosporine, fibric acid derivatives, erythromycin, niacin, azole antifungals, colchicine, telaprevir, boceprevir or the combination of tipranavir/ritonavir. Temporarily w/held or discontinued in any patient w/ acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (eg, severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders & uncontrolled seizures). Measure CK level before starting statin treatment in patients w/ renal impairment, hypothyroidism, personal or familial history of hereditary muscular disorders, previous history of muscular toxicity w/ a statin or fibrate; liver disease &/or where substantial quantities of alcohol are consumed, elderly (>70 yr). Discontinue if clinically significant elevation of CK levels (>10 x ULN) occur or if rhabdomyolysis is diagnosed or suspected. Concomitant treatment w/ ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole & HIV protease inhibitors eg, ritonavir, lopinavir, atazanavir, indinavir, darunavir. Increased risk of myopathy w/ gemfibrozil & other fibric acid derivates, erythromycin, niacin & ezetimibe.